These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 9371066)

  • 1. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood transfusion risk: protecting against the unknown.
    Barbara J; Flanagan P
    BMJ; 1998 Mar; 316(7133):717-8. PubMed ID: 9529394
    [No Abstract]   [Full Text] [Related]  

  • 3. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk?
    Ricketts MN
    CMAJ; 1997 Nov; 157(10):1367-70. PubMed ID: 9371066
    [No Abstract]   [Full Text] [Related]  

  • 5. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
    [No Abstract]   [Full Text] [Related]  

  • 6. Implications of notifying donors and recipients.
    Hewitt PE
    Vox Sang; 2004 Jul; 87 Suppl 2():1-2. PubMed ID: 15209865
    [No Abstract]   [Full Text] [Related]  

  • 7. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 8. vCJD and blood transfusion in the United Kingdom.
    Hewitt P
    Transfus Clin Biol; 2006 Nov; 13(5):312-6. PubMed ID: 17188541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creutzfeldt-Jakob disease and the risk from blood or blood products.
    Will RG; Kimberlin RH
    Vox Sang; 1998; 75(3):178-80. PubMed ID: 9852403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Codon 129 genotype and new variant CJD.
    Zeidler M; Stewart G; Cousens SN; Estibeiro K; Will RG
    Lancet; 1997 Aug; 350(9078):668. PubMed ID: 9288076
    [No Abstract]   [Full Text] [Related]  

  • 11. Look-back notification: how do we assess effectiveness?
    King SM
    CMAJ; 1997 Jul; 157(2):155-7. PubMed ID: 9238144
    [No Abstract]   [Full Text] [Related]  

  • 12. A Canadian hospital-based HIV/hepatitis C look-back notification program.
    Heddle N; Kelton JG; Smaill F; Foss K; Everson J; Janzen C; Walker C; Jones M; Hammons D
    CMAJ; 1997 Jul; 157(2):149-54. PubMed ID: 9238143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of red cell use in 45 hospitals in central Ontario, Canada.
    Chiavetta JA; Herst R; Freedman J; Axcell TJ; Wall AJ; van Rooy SC
    Transfusion; 1996 Aug; 36(8):699-706. PubMed ID: 8780664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.
    Brown P; Gibbs CJ; Rodgers-Johnson P; Asher DM; Sulima MP; Bacote A; Goldfarb LG; Gajdusek DC
    Ann Neurol; 1994 May; 35(5):513-29. PubMed ID: 8179297
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.